Pharmaceutical Thought Leaders 2007 Determining Fair-Market Value and Measuring ROI

Thought leader development is coming under increased scrutiny from regulatory bodies, such as the Health and Human Services Office of Inspector General (OIG), to eliminate the "potential for fraud and abuse" between the pharmaceutical industry and the medical community. Pharmaceutical companies have enacted compliance policies that allow fair-market compensation for thought leaders in exchange for their consultant and advisory services.

The pharmaceutical industry spends millions of dollars each year in payments to key opinion leaders (KOLs) and some experts claim that the number of company-sponsored promotional meetings has risen to more than 250,000 in 2006, which is four times higher than in 1998. With so much money at stake, pharmaceutical companies need to protect themselves from unnecessary regulatory scrutiny and avoid compliance fines.

Although fair-market value payments reduces companies’ liability and removes conflict of interest issues, thought leader managers still struggle to define what fair-market value is. Cutting Edge Information’s latest report on thought leader development provides pharmaceutical companies a solution for segmenting thought leader candidates and defining fair-market value compensations for those segments.

Published 2007

190 Pages

500+ Metrics

161 Tables, Charts and Diagrams

PDF Format
Table of Contents
Price: $7,695.00 / GBP3,847.50